Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Part D Proposal Aims To Promote Biosimilars, Generics To Reduce Costs

Medicare Part D proposed rule would lower cost sharing for biosimilars to the level of generics for some beneficiaries, allow immediate generic substitution for plans.

Medicare Biosimilars

Medicare May Require Part D Plans To Provide Point-of-Sale Rebates

CMS outlines possible approach to point-of-sale rebates in Medicare Part D, recognizing that using rebates to lower cost sharing for 'many' would increase premiums for all.

Pricing Debate Pharmacy Benefit Management

OMB's Grogan Talks Drug Pricing And Taking On 'Sacred Cows'

Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.

Pricing Debate Reimbursement

HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority

Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.

Pricing Debate Government Payers

Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition

FTC Acting Chairman Ohlhausen predicts agency will continue to focus on competition issues involving barriers to generics but says 'we need to learn more about how these markets are working today.'

Pricing Debate Legal Issues

Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'

Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.

Biosimilars Medicare
See All
Advertisement
UsernamePublicRestriction

Register